title: Quality assurance after process changes of the production of a therapeutic antibody.
abstract: Process development for the production of a therapeutic humanised antibody is a very complex operation. It involves recombinant genetics, verification of a strong expression system, gene amplification, characterisation of a stable host cell expression system, optimisation and design of the mammalian cell culture fermentation system and development of an efficient recovery process resulting in high yields and product quality. Rapid progress in the field and the wish of some pharmaceutical companies for outsourcing their production are the driving forces for process changes relatively late in the development phase. This literature survey is aimed at identifying the limits of acceptable process changes in up scaling of the fermentation and down stream processing of biopharmaceuticals and defining the demand in production validation to prove product equivalency and identity of the isolated, purified therapeutic antibody.
authors.affiliation: LONZA AG, Forschung Biotech, Visp, Switzerland.
authors.forename: J M
authors.initials: JM
authors.lastname: Brass
authors.forename: K
authors.initials: K
authors.lastname: Krummen
authors.forename: C
authors.initials: C
authors.lastname: Moll-Kaufmann
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000917:Antibody Formation; D016466:CHO Cells; D002626:Chemistry, Pharmaceutical / Q000592:standards*; D006224:Cricetinae; D006801:Humans; D011786:Quality Control
chemical_list: D000906:Antibodies